Brief: Crossject FY Operating Income Up At EUR 12.82 Mln

Crossject SA

02/04/2024 09:52

April 2 (Reuters) - Crossject SA  74C.F :
    * REDUCED 2023 NET LOSS OF EUR 8.5 MILLION VERSUS EUR 11.2
MILLION
IN 2022
    * FY OPERATING INCOME EUR 12.82 MILLION, UP VERSUS EUR 9.71
MILLION YOY
    * EXPECTATION TO RECEIVE U.S. EMERGENCY USE AUTHORIZATION
(EUA)
FOR ZEPIZURE® IN Q1 2025
    * EXPECTATION TO COMPLETE U.S. NEW DRUG APPLICATION (NDA)
FOR
ZEPIZURE® IN H1 2025
    * AS OF 31 DECEMBER 2023, WE HAD A CASH BALANCE OF EUR 2.3
MILLION
    * ZENEO HYDROCORTISONE AND ZENEO ADRENALINE, ARE ALSO
PROGRESSING
TOWARD PLANNED MARKET AUTHORIZATION FILINGS IN 2025 AND 2026
RESPECTIVELY

Source text for Eikon:  ID:nGNX829zFs 
Further company coverage:  74C.F 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))